← Back to Search

Tyrosine Kinase Inhibitor

Sitravatinib for Breast Cancer

Phase 2
Waitlist Available
Research Sponsored by Xiang Zhang
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 16 months
Awards & highlights
No Placebo-Only Group

Summary

This trial tests sitravatinib, a pill taken regularly, in patients with advanced breast cancer. The medication aims to stop the cancer from getting worse by blocking proteins that help cancer cells grow.

Eligible Conditions
  • Breast Cancer
  • Breast cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 16 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 16 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Efficacy: Progression-Free Survival at 24 Weeks (PFS24)
Secondary study objectives
Clinical Benefit Rate (CBR)
Number of Participants With Grade 3 or Higher AEs
Objective Response Rate (ORR)
+1 more

Side effects data

From 2023 Phase 2 trial • 25 Patients • NCT03680521
86%
Hypertension
71%
Dysphonia
57%
Headache
43%
Fatigue
43%
Constipation
43%
Lipase increased
43%
Oral dysaesthesia
29%
Blood thyroid stimulating hormone increased
29%
Pain
29%
Hypothyroidism
29%
Vomiting
29%
Diarrhoea
29%
Hypotension
29%
Myalgia
29%
Urinary tract infection
29%
Amylase increased
14%
Chills
14%
Herpes zoster
14%
Acute respiratory failure
14%
Flank pain
14%
Cough
14%
Alanine aminotransferase increased
14%
Epistaxis
14%
Night sweats
14%
Weight decreased
14%
Abdominal pain
14%
Arthralgia
14%
Hyperuricaemia
14%
Memory impairment
14%
Musculoskeletal pain
14%
Nasal congestion
14%
Urinary retention
14%
Nausea
14%
Rash
14%
Decreased appetite
14%
Dizziness
14%
Haematuria
14%
Nail discolouration
14%
Hypoglycaemia
14%
Oral herpes
14%
Pain in jaw
14%
Pneumonitis
14%
Procedural pain
14%
Pyrexia
14%
Rhinitis allergic
14%
Rhinorrhoea
14%
Sinus congestion
14%
Somnolence
14%
Thrombocytopenia
14%
Tinnitus
14%
Tooth abscess
14%
Urosepsis
14%
Atrial fibrillation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Sitravatinib 120 mg
Sitravatinib 80 mg

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: SitravatinibExperimental Treatment1 Intervention
Sitravatinib 100 mg daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sitravatinib
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Xiang ZhangLead Sponsor
1 Previous Clinical Trials
64 Total Patients Enrolled
Mirati Therapeutics Inc.Industry Sponsor
70 Previous Clinical Trials
8,126 Total Patients Enrolled
1 Trials studying Breast Cancer
54 Patients Enrolled for Breast Cancer
C. Kent Osborne, MDLead Sponsor
~1 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top